Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: GlobeNewswire
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that three abstracts relating to the company’s lead product candidate, tipifarnib, and ERK inhibitor, KO-947, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2018, which will be held from April 14-18, 2018 in Chicago. The following abstracts are now available on the AACR website at www.aacr.org. Tipifarnib is Highly Active in HRAS Mutant Lung Squamous Carcinoma TumorModels (Abstract # 4917)Session Category: Experimental and Molecular TherapeuticsSession Title: Pharmacokinetics and PharmacodynamicsSession Date and Time: Tuesday, April 17, 2018, 1:00 p.m. - 5:00 p.m.Location: McCormick Place South, Exhibit Hall A, Poster Section 41 11q13 Amplification Selects for Sensitivity to the ERK Inhibitor KO-947 inSquamous Cell Carcinomas (Abst
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology to Report First Quarter 2024 Financial ResultsGlobeNewswire
- Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML [Yahoo! Finance]Yahoo! Finance
- Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLGlobeNewswire
- Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
KURA
Earnings
- 2/27/24 - Beat
KURA
Sec Filings
- 4/18/24 - Form ARS
- 4/12/24 - Form DEF
- 4/12/24 - Form DEFA14A
- KURA's page on the SEC website